These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33046518)

  • 21. Phase 1b/2 study of penpulimab (AK105), an antiprogrammed cell death-1 immunoglobulin G1 antibody, in advanced or metastatic solid tumors (AK105-204).
    Zheng Y; Zhu J; Xiong J; Jiang O; Wang H; Xie Y; Zhou Y; Xu N
    Cancer; 2024 Jun; 130(12):2180-2190. PubMed ID: 38412283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
    Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
    Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma.
    Jagodzińska-Mucha P; Świtaj T; Kozak K; Koseła-Paterczyk H; Klimczak A; Ługowska I; Rogala P; Wągrodzki M; Falkowski S; Rutkowski P
    Tumori; 2017 May; 103(3):231-235. PubMed ID: 28291905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
    Zhao J; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
    Strosberg J; Mizuno N; Doi T; Grande E; Delord JP; Shapira-Frommer R; Bergsland E; Shah M; Fakih M; Takahashi S; Piha-Paul SA; O'Neil B; Thomas S; Lolkema MP; Chen M; Ibrahim N; Norwood K; Hadoux J
    Clin Cancer Res; 2020 May; 26(9):2124-2130. PubMed ID: 31980466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.
    Xia L; Wang J; Wang C; Zhang Q; Zhu J; Rao Q; Cheng H; Liu Z; Yin Y; Ai X; Gulina K; Zheng H; Luo X; Chang B; Li L; Liu H; Li Y; Lou G; Zhou Q; Zhu Y; Xiao Z; Tong J; Wang K; Chen J; Wang X; Song L; Wei Z; Ye Y; Zhu J; Wu X
    Int J Gynecol Cancer; 2023 Dec; 33(12):1861-1868. PubMed ID: 37875323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.
    Yang J; Dong L; Yang S; Han X; Han Y; Jiang S; Yao J; Zhang Z; Zhang S; Liu P; Qin Y; Wu H; Feng H; Yao S; Sun Y; Song H; Shi Y
    Eur J Cancer; 2020 May; 130():182-192. PubMed ID: 32224416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
    Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
    J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
    Tawbi HA; Burgess M; Bolejack V; Van Tine BA; Schuetze SM; Hu J; D'Angelo S; Attia S; Riedel RF; Priebat DA; Movva S; Davis LE; Okuno SH; Reed DR; Crowley J; Butterfield LH; Salazar R; Rodriguez-Canales J; Lazar AJ; Wistuba II; Baker LH; Maki RG; Reinke D; Patel S
    Lancet Oncol; 2017 Nov; 18(11):1493-1501. PubMed ID: 28988646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
    Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry.
    Hindi N; Razak A; Rosenbaum E; Jonczak E; Hamacher R; Rutkowski P; Bhadri VA; Skryd A; Brahmi M; Alshibany A; Jagodzinska-Mucha P; Bauer S; Connolly E; Gelderblom H; Boye K; Henon C; Bae S; Bogefors K; Vincenzi B; Martinez-Trufero J; Lopez-Martin JA; Redondo A; Valverde C; Blay JY; Moura DS; Gutierrez A; Tap W; Martin-Broto J
    ESMO Open; 2023 Dec; 8(6):102045. PubMed ID: 38016251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
    Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
    Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma.
    Huang J; Xu B; Mo H; Zhang W; Chen X; Wu D; Qu D; Wang X; Lan B; Yang B; Wang P; Zhang H; Yang Q; Jiao Y
    Clin Cancer Res; 2018 Mar; 24(6):1296-1304. PubMed ID: 29358502
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
    Phuphanich S; Raizer J; Chamberlain M; Canelos P; Narwal R; Hong S; Miday R; Nade M; Laubscher K
    J Neurooncol; 2017 Jan; 131(1):185-191. PubMed ID: 27844311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.